Yong Sheng Jiao; Denial of Hearing; Final Debarment Order
Published Date: 1/8/2025
Notice
Summary
Yong Sheng Jiao has been banned for 5 years from importing any drugs into the U.S. because he was convicted of a serious crime related to drug importation. The FDA denied his request for a hearing since he didn’t provide enough info to challenge the ban. This order starts on January 8, 2025, and Jiao can apply to end the ban early by following FDA rules.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
Five-year debarment from importing drugs
The FDA has debarred Yong Sheng Jiao for 5 years from importing or offering for import any drug into the United States, effective January 8, 2025. The debarment is based on his 2023 guilty plea and 2024 federal judgment for knowingly introducing misbranded dipyrone into interstate commerce.
Helping him import drugs is prohibited
As of January 8, 2025, importing or offering for import any drug into the United States by, with the assistance of, or at the direction of Yong Sheng Jiao is a prohibited act under the FD&C Act (section 301(cc)). Businesses or individuals who import drugs in cooperation with Jiao would be engaging in a prohibited act under that statutory provision.
Right to apply to end debarment early
The debarred individual may apply for termination of debarment under section 306(d) of the FD&C Act. Applications may be submitted electronically via https://www.regulations.gov (which will be posted publicly) or as written/paper submissions with procedures for marking confidential information.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Related Federal Register Documents
2026-20709, Self-Regulatory Organizations; Cboe EDGX Exchange, Inc.; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change To Amend Rule 11.15 (Clearly Erroneous Executions)
Cboe EDGX Exchange is updating its rule about fixing trading mistakes to match new overnight trading hours. This change affects traders using the Exchange by clarifying how errors during extended hours are handled. The update is effective immediately, helping keep trading fair and smooth without extra costs or delays.
2026-20708, Self-Regulatory Organizations; Investors Exchange LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Pursuant to IEX Rule 15.110(a) and (c) To Amend the IEX Equities Fee Schedule
IEX is shaking up its fee schedule starting November 1, 2026, by tweaking who gets rebates for adding displayed liquidity and changing rebate amounts. This affects IEX members who trade stocks, giving them new ways to save or earn more on fees. The changes kick in right away after filing, so traders should get ready to adjust their strategies and cash flow.
2026-20702, Notice of Public Meetings of the Virginia Advisory Committee to the U.S. Commission on Civil Rights
The Virginia Advisory Committee to the U.S. Commission on Civil Rights is holding virtual public meetings to discuss how Virginia public universities are following rules about fair student admissions. Anyone interested can join these Zoom meetings on October 27, November 10, and December 15, 2026, to listen and share their thoughts. These meetings don’t cost money to attend, but phone users might pay regular call fees.
2026-20706, Self-Regulatory Organizations; MEMX LLC; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change To Amend the Exchange's Fee Schedule
MEMX is updating its fee schedule to change the rules for a special discount called Tape B Volume Tier 2. This affects members who trade a lot on the exchange and could change how much they pay in fees. The new rules kick in right away, so members should check how this might impact their costs now.
2026-20707, Self-Regulatory Organizations; MEMX LLC; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change To Amend the Exchange's Fee Schedule
MEMX is updating its options trading fees starting October 1, 2026. They’re renaming a volume discount tier and tweaking which trades count for discounts. This change mainly affects traders using MEMX’s options platform and could impact how much they pay in fees.
2026-20705, Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Antibody Specifically Binding to Severe Fever With Thrombocytopenia Syndrome Virus Antigen and Use Thereof
The National Institute of Allergy and Infectious Diseases plans to give Korea National Institute of Health an exclusive license to develop and sell a special antibody that targets a dangerous virus causing severe fever and low platelets. This deal helps speed up turning the invention into real-world treatments. Comments or license requests must be sent by October 26, 2026.
Previous / Next Documents
Previous: 2025-00125, Withdrawal of Food and Drug Administration Notice Regarding Yong Sheng Jiao; Denial of Hearing; Final Debarment Order
The FDA is pulling back its December 5, 2024, notice about Yong Sheng Jiao’s debarment because it had mistakes and left out important info. They’re fixing the errors and publishing a corrected version soon. This affects Yong Sheng Jiao’s official record and clears up confusion about the debarment details.
Next: 2025-00128, Agency Information Collection Activities: Comment Request
The Social Security Administration wants your thoughts on how they collect info online, like using passwords instead of paper signatures. This affects businesses and people who use their online services, aiming to make things easier and faster without extra hassle. You’ve got until February 7, 2025, to share your ideas and help improve the process—no extra cost, just your feedback!